Work

A phase 1/2 study of BLU-945 in patients with common activating EGFR-mutant non–small cell lung cancer (NSCLC): SYMPHONY trial in progress.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.tps9156

Authors: Elaine Shum, Yasir Y Elamin, Zofia Piotrowska, David R Spigel, Karen L. Reckamp, Julia K Rotow, Daniel Shao-Weng Tan, Sun Min Lim, Tae Min Kim, Chia-Chi Lin, Terufumi Kato, Jagan Parepally, Faris Albayya, Melinda Louie-Gao, Tessa Weinig, Alena Zalutskaya, Koichi Goto

Institutions: NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, New York University, The University of Texas MD Anderson Cancer Center, Massachusetts General Hospital, Sarah Cannon, Tennessee Oncology, Cedars-Sinai Medical Center, Dana-Farber Cancer Institute, National Cancer Centre Singapore, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Seoul National University, Seoul National University Hospital, National Taiwan University Hospital, Kanagawa Cancer Center, Blueprint Medicines (United States), National Cancer Center Hospital East

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4286297233

Cites:

Cited by: 18

Related to: 10